# Reporting adverse incidents: neurostimulators

Source: https://www.keypedia.com/records/uk_mhra_guidance/uk-mhra/ec7eac87-53e2-4dd8-9df8-c47c2365ebab
Type: Guidance
Published: May 31, 2013
Updated: January 15, 2025

> This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the mandatory reporting requirements for manufacturers regarding adverse incidents involving stimulator devices. Operating under the framework of the UK Medical Devices Regulations 2002, the document serves as a critical component of the medical device vigilance system. While it is not a report for a specific company or inspection date, it establishes the legal standards for all manufacturers operating in the UK. The main issues addressed include malfunctions, performance deterioration, or labeling inadequacies that could potentially lead to serious health issues or death. Manufacturers are required to implement systematic monitoring and must submit detailed incident reports to the MHRA within specific timeframes based on the severity of the event. Required actions include performing rigorous root cause analyses for any reported failures and executing corrective measures to mitigate future risks. By following these protocols, manufacturers ensure transparent communication with regulatory bodies, allowing for the timely identification of safety trends and the protection of the public from defective medical technology.

---

## Content

Guidance for manufacturers on reporting adverse incidents involving stimulators under the vigilance system. To be read in conjunction with the guidelines on post-market surveillance .

## Attachments

- [Device-specific vigilance guidance: neurostimulators ](/government/publications/reporting-adverse-incidents-neurostimulators/device-specific-vigilance-guidance-neurostimulators)